Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...
Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback